Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. - Wikidata - wikimedia - TriplyDB

Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

http://www.wikidata.org/entity/Q40774514

about

Anti-hepatitis C virus drugs and kidney Hepatitis C Therapy in Renal Patients: Who, How, When?Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience.Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens.Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations.Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function.Hepatitis C Virus Infection in Chronic Kidney Disease.Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions.Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients.Management of Post-Liver Transplant Recurrence of Hepatitis C.Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.Treatment Options in Hepatitis C.Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease.Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD.Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment.Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia.Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen.Decreasing Mortality and Disease Severity in Hepatitis C Patients Awaiting Liver Transplantation in the United States.Clinical trials: Treatment of HCV-infected patients with advanced kidney disease.Transplantation of Kidneys from HCV-Positive Donors: How to Best Use a Scarce Resource.Use of sofosbuvir in chronic kidney disease: Is it necessary?Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C.Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction.

P2860

Q28070279-A373C450-EEBC-41A1-808D-479DBB5764B9 Q28077130-92E1B642-EB57-41F0-A9CC-E9725FBA4B67 Q28077263-B83532AF-9D4F-4D05-9A76-606740F621B0 Q31143582-A944C8E0-2FEF-4E49-915C-1B8CFDE6D551 Q33440016-754FFC4D-EF0D-4AC1-8D2C-BF25BC429948 Q33621619-024E0A3F-4BD3-4412-A603-228596AE3A9B Q33845581-3121B29B-6448-4AC5-8463-EA2D90ABE43F Q36220536-3D5E7C3E-89D8-4E4D-B0B4-A891DB378867 Q37555313-4DFF400A-6CA1-4BCE-8F53-EDDD74F41465 Q38615384-6B60A513-DABA-4067-8170-65AC9AC74AFF Q38812607-C84DD0FB-E945-4E69-A27A-311D67DDAC84 Q38860565-303D397B-1C02-4260-B506-12242C3ACE3D Q38875903-BF68149C-0205-4191-AE02-54FC2D5217E3 Q38975165-015631F8-2E1E-4827-B25A-BA946F94E5AD Q39017681-F5EDFA97-4CA6-4C90-B7D9-98602E316B8E Q39067369-494653D5-6FC4-41EB-B5C6-BBB723489484 Q39092977-E8C3D817-BFAA-4288-B742-E3F8AA6B9A3C Q39099569-90BB6CF3-95BB-49A5-A3E8-6CD7F2FCE40F Q39112237-DBE3B77B-B7DA-4288-8345-87EB37EF737D Q39455853-70A0AEE8-937A-450E-B4F1-80C52BE1C2EC Q40052523-68C8D724-8884-4102-9C0C-871F71ABA43D Q40089989-A25179C5-18D1-4423-BF3F-22A14E0513DF Q40215846-AF5024C5-28CD-4595-B3D2-003830CC1E7F Q40278746-E19A6ED6-9A01-4C60-BBD8-B6844C69B6AA Q40413390-711A90A0-9978-402A-BED0-57FF41695F54 Q40444467-30A155A6-0EC3-49CE-AF56-D42F8FF1C53E Q40476119-992373AC-1023-494D-954D-3B0CD9569218 Q40708768-0F34A483-CB27-4757-A160-2DCACBA50D51 Q41925546-64B92AC6-D542-486D-A634-0D483974030C Q42370354-EB29E20E-5E3C-43D4-8F03-929658FEA848 Q45325791-7AE64798-6BCC-4254-94C8-D95F47A71A81 Q47108436-5E76B62E-4EC4-4EE6-AD28-626926275607 Q47583932-51087507-4665-4897-ACD7-920F9FCBDCDA Q47695767-B6FFFC9C-87A7-4CE5-8C61-B6615819E1EA Q47777226-04BE9E91-54B3-4F2D-85CB-9DE56624280D Q48096472-50F4F469-EC37-437B-A640-740369DC4E17 Q48507049-B228841F-F97A-4ADF-9EEF-96E9AA3E343C Q49200882-729B2F98-858D-4803-B873-0C7E6ADC61A7 Q50208930-988650C5-88B2-43A3-9FCE-772CD7341231 Q51754955-DA072B26-72FA-444A-89A7-5E49EB200337

P2860

Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

http://www.wikidata.org/entity/Q40774514

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Safety and efficacy of sofosbu ...... with impaired renal function.

@en

type

label

Safety and efficacy of sofosbu ...... with impaired renal function.

@en

prefLabel

Safety and efficacy of sofosbu ...... with impaired renal function.

@en

P1433

Q40774514-971C1411-80A7-402A-9E63-9858674057C1

P1476

Q40774514-431AB4E6-B86B-4509-9FAE-31B3681BB60F

P2093

Q40774514-1AD58572-8B94-4EAA-BD5F-EC969CF8DBA5

Q40774514-2BD1FE71-DC51-4247-96A9-4C73A83D8770

Q40774514-36F144CA-0EA6-4DA1-8D7F-717CBBE358EC

Q40774514-52468243-C877-41CC-9883-553BD19F1A85

Q40774514-771E962D-D8A1-448A-8AF9-204783EBD932

Q40774514-AC0AC02E-460B-4A5F-98F2-5B559171AB98

Q40774514-B331AB2B-F10F-41E1-BBAD-AC1D6A940BB2

Q40774514-CE8D2830-155B-47A0-9650-C89A52F80AD3

Q40774514-D9E80541-35B6-4B37-9664-D98F82B10F66

Q40774514-F11A7BDB-39D1-4099-806A-68FE872EAACB

P2860

Q40774514-1FEF9536-740A-4F62-88D3-8E26308E49AA

Q40774514-29221681-2CBE-405E-829D-237405EF557B

Q40774514-2AFC023A-AC71-475D-843D-1EED58048885

Q40774514-2C5F2331-75C2-41A5-8955-7847A5CA85E6

Q40774514-3F2C1139-E044-4C24-A244-239999FF32AE

Q40774514-69209FAF-2DE4-4288-B540-CEF73B59474C

Q40774514-71128BE7-D512-4F50-9B88-AA6BCDA488AD

Q40774514-75584C43-032B-4B14-9AF8-54769A8ADC4E

Q40774514-8224807B-9F9A-414D-BF82-02A7DBDA86C8

Q40774514-9063EF3C-9F6C-4AD1-ABC5-8F6A053DAB0E

P304

Q40774514-DD2DEC4F-6223-4639-9E1B-8B30159DCC72

P31

Q40774514-5365A00E-227C-4449-BC49-092B27832F68

P356

Q40774514-616F04B2-90CE-4F7E-9775-0AC0362F8629

P433

Q40774514-63F66D2D-5392-4302-83E3-623FD2FDFB93

P478

Q40774514-AA2F3C45-9727-4C07-8EDF-2DDB515A57F8

P50

Q40774514-DA7D79B8-7EF5-44B3-A169-B53CA92C0B01

P577

Q40774514-73F1EC23-067E-47CF-955F-0637FC4C1FC7

P698

Q40774514-BF86824D-E527-41B2-A087-4214AA90F102

P921

Q40774514-4D2830D7-B99A-4B5D-BBC6-D85A69B680A8

P932

Q40774514-0FF021D1-0C3B-4AB7-A7CA-3C17A27900F2

P356

P1433

Liver International

P1476

Safety and efficacy of sofosbu ...... s with impaired renal function

@en

P2093

Annmarie Liapakis

http://www.w3.org/2001/XMLSchema#string

David R Nelson

http://www.w3.org/2001/XMLSchema#string

Farrukh M Koraishy

http://www.w3.org/2001/XMLSchema#string

HCV-TARGET

http://www.w3.org/2001/XMLSchema#string

Joseph K Lim

http://www.w3.org/2001/XMLSchema#string

Meghan E Sise

http://www.w3.org/2001/XMLSchema#string

Michael W Fried

http://www.w3.org/2001/XMLSchema#string

Norah A Terrault

http://www.w3.org/2001/XMLSchema#string

Raymond T Chung

http://www.w3.org/2001/XMLSchema#string

Varun Saxena

http://www.w3.org/2001/XMLSchema#string

P2860

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease.

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.

Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency.

Acute kidney injury in cirrhosis.

Early use of renal-sparing agents in liver transplantation: a closer look.

Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis.

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir.

P304

807-816

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LIV.13102

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Monica L Schmidt

P577

2016-02-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26923436

http://www.w3.org/2001/XMLSchema#string

P921

P932

6453817

http://www.w3.org/2001/XMLSchema#string